Tema Etfs LLC Buys Shares of 4,598 argenx SE (NASDAQ:ARGX)

Tema Etfs LLC acquired a new stake in shares of argenx SE (NASDAQ:ARGX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 4,598 shares of the company's stock, valued at approximately $2,828,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Assenagon Asset Management S.A. grew its position in argenx by 21.4% in the 4th quarter. Assenagon Asset Management S.A. now owns 34,955 shares of the company's stock worth $21,497,000 after purchasing an additional 6,161 shares during the period. Park Avenue Securities LLC lifted its holdings in argenx by 40.0% in the fourth quarter. Park Avenue Securities LLC now owns 1,695 shares of the company's stock valued at $1,042,000 after acquiring an additional 484 shares during the period. Ritholtz Wealth Management boosted its position in argenx by 85.5% in the fourth quarter. Ritholtz Wealth Management now owns 898 shares of the company's stock worth $552,000 after purchasing an additional 414 shares during the last quarter. Aaron Wealth Advisors LLC grew its stake in shares of argenx by 10.1% during the 4th quarter. Aaron Wealth Advisors LLC now owns 489 shares of the company's stock valued at $301,000 after purchasing an additional 45 shares during the period. Finally, Ballentine Partners LLC increased its position in shares of argenx by 21.5% during the 4th quarter. Ballentine Partners LLC now owns 536 shares of the company's stock valued at $330,000 after purchasing an additional 95 shares during the last quarter. Institutional investors own 60.32% of the company's stock.

Wall Street Analyst Weigh In

ARGX has been the subject of a number of research reports. Robert W. Baird raised shares of argenx from a "neutral" rating to an "outperform" rating and set a $680.00 target price for the company in a report on Tuesday, May 13th. Guggenheim decreased their price objective on shares of argenx from $1,100.00 to $1,065.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. HC Wainwright reaffirmed a "buy" rating and issued a $720.00 target price on shares of argenx in a report on Tuesday, April 8th. William Blair reiterated an "outperform" rating on shares of argenx in a research report on Friday, February 28th. Finally, JMP Securities set a $699.00 price target on argenx in a report on Wednesday, May 14th. One investment analyst has rated the stock with a hold rating, twenty have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, argenx has an average rating of "Buy" and a consensus price target of $698.11.

argenx Trading Down 0.2%

Shares of NASDAQ ARGX traded down $1.18 during midday trading on Friday, hitting $580.27. The company's stock had a trading volume of 94,204 shares, compared to its average volume of 324,315. argenx SE has a 12-month low of $358.80 and a 12-month high of $678.21. The firm has a market cap of $35.43 billion, a P/E ratio of -658.92 and a beta of 0.57. The business's 50 day moving average is $590.25 and its two-hundred day moving average is $612.93.

argenx (NASDAQ:ARGX - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $2.58 earnings per share for the quarter, topping analysts' consensus estimates of $2.32 by $0.26. The business had revenue of $1.35 billion for the quarter, compared to analyst estimates of $748.34 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. On average, analysts predict that argenx SE will post 3.13 earnings per share for the current fiscal year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.